SillaJen Inc

SillaJen, Inc. develops technologies and products using genetic engineering in South Korea, together with its subsidiaries. Its clinical pipeline includes Pexa-Vec, which is in a phase 2 trial for renal cell carcinoma and prostate cancer and a phase 1 trial for melanoma and solid tumors. The company also develops BAL0891 in a phase 1 trial for solid tumors, and the SJ-600 Series and JX-970 for solid tumors in preclinical trials. Founded in 2006, SillaJen is headquartered in Seoul, South Korea, and operates in the biotechnology research industry.